Surprises from Genetic Analyses of Lipid Risk Factors for Atherosclerosis

Circulation Research

Volumn 118, Issue 4, 2016, Pages 579-585

  Musunuru, Kiran ^a,b,c   Kathiresan, Sekar ^a,c,d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

atherosclerosis; coronary disease; genetics; lipoproteins; triglycerides

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANGIOPOIETIN LIKE 4; APOLIPOPROTEIN A5; APOLIPOPROTEIN B; APOLIPOPROTEIN C3; BIOLOGICAL MARKER; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN A; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ANTILIPEMIC AGENT; GENETIC MARKER; PLA2G7 PROTEIN, HUMAN;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; CORONARY ARTERY DISEASE; GAIN OF FUNCTION MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; HUMAN GENETICS; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; LOSS OF FUNCTION MUTATION; MENDELIAN RANDOMIZATION ANALYSIS; PLEIOTROPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE NUCLEOTIDE POLYMORPHISM; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; BLOOD; DYSLIPIDEMIAS; GENETIC MARKER; GENETIC PREDISPOSITION; GENETICS; LIPID METABOLISM; PHENOTYPE; PRIMARY PREVENTION; PROCEDURES; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANIMALS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; DYSLIPIDEMIAS; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPOLIPIDEMIC AGENTS; LIPID METABOLISM; LIPOPROTEIN(A); PHENOTYPE; PRIMARY PREVENTION; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; TRIGLYCERIDES;

EID: 84959046869     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.115.306398     Document Type: Article

References (55)

1. Lloyd-Jones DM, Nam BH, D'Agostino RB Sr, Levy D, Murabito JM, Wang TJ, Wilson PW, O'Donnell CJ., Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: a prospective study of parents and offspring. JAMA 2004 291 2204 2211
2. Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, Wood AM, Lewington S, Sattar N, Packard CJ, Collins R, Thompson SG, Danesh J, Emerging Risk Factors Collaboration Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009 302 1993 2000. doi: 10.1001/jama.2009.1619.
3. Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, Boekholdt SM, Khaw KT, Gudnason V., Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007 115 450 458. doi: 10.1161/CIRCULATIONAHA.106.637793.
4. Emerging Risk Factors Collaboration Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, White IR, Marcovina SM, Collins R, Thompson SG, Danesh J., Emerging Risk Factors Collaboration Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009 302 412 423
5. Heller DA, de Faire U, Pedersen NL, Dahlén G, McClearn GE., Genetic and environmental influences on serum lipid levels in twins. N Engl J Med 1993 328 1150 1156. doi: 10.1056/NEJM199304223281603.
6. Rader DJ, Cohen J, Hobbs HH., Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J Clin Invest 2003 111 1795 1803. doi: 10.1172/JCI18925.
7. Teslovich TM, Musunuru K, Smith AV, Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010 466 707 713. doi: 10.1038/nature09270.
8. Global Lipids Genetics Consortium Willer CJ, Schmidt EM, Sengupta S, Global Lipids Genetics Consortium Discovery and refinement of loci associated with lipid levels. Nat Genet 2013 45 1274 1283
9. Peloso GM, Auer PL, Bis JC, NHLBI GO Exome Sequencing Project Association of low-frequency and rare coding-sequence variants with blood lipids and coronary heart disease in 56,000 whites and blacks. Am J Hum Genet 2014 94 223 232. doi: 10.1016/j.ajhg.2014.01.009.
10. Lange LA, Hu Y, Zhang H, NHLBI Grand Opportunity Exome Sequencing Project Whole-exome sequencing identifies rare and low-frequency coding variants associated with LDL cholesterol. Am J Hum Genet 2014 94 233 245. doi: 10.1016/j.ajhg.2014.01.010.
11. Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes J 3rd., Factors of risk in the development of coronary heart disease-six year follow-up experience. The Framingham Study. Ann Intern Med 1961 55 33 50
12. Smith GD, Ebrahim S., 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 2003 32 1 22
13. Sheehan NA, Didelez V, Burton PR, Tobin MD., Mendelian randomisation and causal inference in observational epidemiology. PLoS Med 2008 5 e177. doi: 10.1371/journal.pmed.0050177.
14. Lehrman MA, Schneider WJ, Südhof TC, Brown MS, Goldstein JL, Russell DW., Mutation in LDL receptor: Alu-Alu recombination deletes exons encoding transmembrane and cytoplasmic domains. Science 1985 227 140 146
15. Soria LF, Ludwig EH, Clarke HR, Vega GL, Grundy SM, McCarthy BJ., Association between a specific apolipoprotein B mutation and familial defective apolipoprotein B-100. Proc Natl Acad Sci USA 1989 86 587 591
16. Abifadel M, Varret M, Rabès JP, Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003 34 154 156. doi: 10.1038/ng1161.
17. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH., Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006 354 1264 1272. doi: 10.1056/NEJMoa054013.
18. Voight BF, Peloso GM, Orho-Melander M, Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study. Lancet 2012 380 572 580. doi: 10.1016/S0140-6736(12)60312-2.
19. Clarke R, Peden JF, Hopewell JC, PROCARDIS Consortium Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009 361 2518 2528. doi: 10.1056/NEJMoa0902604.
20. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG., Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 2009 301 2331 2339. doi: 10.1001/jama.2009.801.
21. Kapur NK, Musunuru K., Clinical efficacy and safety of statins in managing cardiovascular risk. Vasc Health Risk Manag 2008 4 341 353
22. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E, Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005 352 20 28. doi: 10.1056/NEJMoa042378.
23. Garcia-Calvo M, Lisnock J, Bull HG, The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci USA 2005 102 8132 8137. doi: 10.1073/pnas.0500269102.
24. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, Visseren FL, Sijbrands EJ, Trip MD, Stein EA, Gaudet D, Duivenvoorden R, Veltri EP, Marais AD, de Groot E, ENHANCE Investigators Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008 358 1431 1443. doi: 10.1056/NEJMoa0800742.
25. Myocardial Infarction Genetics Consortium Investigators Stitziel NO, Won HH, Morrison AC, Myocardial Infarction Genetics Consortium Investigators Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med 2014 371 2072 2082
26. Ference BA, Majeed F, Penumetcha R, Flack JM, Brook RD., Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 × 2 factorial Mendelian randomization study. J Am Coll Cardiol 2015 65 1552 1561. doi: 10.1016/j.jacc.2015.02.020.
27. Cannon CP, Blazing MA, Giugliano RP, IMPROVE-IT Investigators Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015 372 2387 2397. doi: 10.1056/NEJMoa1410489.
28. Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, Wasserman SM, Scott R, Koren MJ, Stein EA, Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015 372 1500 1509. doi: 10.1056/NEJMoa1500858.
29. Robinson JG, Farnier M, Krempf M, ODYSSEY LONG TERM Investigators Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015 372 1489 1499. doi: 10.1056/NEJMoa1501031.
30. Frikke-Schmidt R., Genetic variation in the ABCA1 gene, HDL cholesterol, and risk of ischemic heart disease in the general population. Atherosclerosis 2010 208 305 316. doi: 10.1016/j.atherosclerosis.2009.06.005.
31. Barter PJ, Caulfield M, Eriksson M, ILLUMINATE Investigators Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007 357 2109 2122. doi: 10.1056/NEJMoa0706628.
32. Schwartz GG, Olsson AG, Abt M, dal-OUTCOMES Investigators Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012 367 2089 2099. doi: 10.1056/NEJMoa1206797.
33. Eli Lilly and Company Lilly to Discontinue Development of Evacetrapib for High-risk Atherosclerotic Cardiovascular disease. https://investor.lilly.com/releasedetail.cfm?releaseid=936130. Accessed October 31, 2015
34. Thompson A, Di Angelantonio E, Sarwar N, Erqou S, Saleheen D, Dullaart RP, Keavney B, Ye Z, Danesh J., Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA 2008 299 2777 2788. doi: 10.1001/jama.299.23.2777.
35. Ridker PM, Paré G, Parker AN, Zee RY, Miletich JP, Chasman DI., Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: Genomewide analysis among 18 245 initially healthy women from the Women's Genome Health Study. Circ Cardiovasc Genet 2009 2 26 33. doi: 10.1161/CIRCGENETICS.108.817304.
36. Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration Sarwar N, Sandhu MS, Ricketts SL, Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 2010 375 1634 1639
37. Jørgensen AB, Frikke-Schmidt R, West AS, Grande P, Nordestgaard BG, Tybjærg-Hansen A., Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. Eur Heart J 2013 34 1826 1833. doi: 10.1093/eurheartj/ehs431.
38. Do R, Stitziel NO, Won HH, NHLBI Exome Sequencing Project Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. Nature 2015 518 102 106. doi: 10.1038/nature13917.
39. Pollin TI, Damcott CM, Shen H, Ott SH, Shelton J, Horenstein RB, Post W, McLenithan JC, Bielak LF, Peyser PA, Mitchell BD, Miller M, O'Connell JR, Shuldiner AR., A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science 2008 322 1702 1705. doi: 10.1126/science.1161524.
40. TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute Crosby J, Peloso GM, Auer PL, TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med 2014 371 22 31
41. Jørgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybjærg-Hansen A., Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med 2014 371 32 41. doi: 10.1056/NEJMoa1308027.
42. Folsom AR, Peacock JM, Demerath E, Boerwinkle E., Variation in ANGPTL4 and risk of coronary heart disease: the Atherosclerosis Risk in Communities Study. Metabolism 2008 57 1591 1596. doi: 10.1016/j.metabol.2008.06.016.
43. Varbo A, Benn M, Tybjærg-Hansen A, Jørgensen AB, Frikke-Schmidt R, Nordestgaard BG., Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol 2013 61 427 436. doi: 10.1016/j.jacc.2012.08.1026.
44. Do R, Willer CJ, Schmidt EM, Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet 2013 45 1345 1352. doi: 10.1038/ng.2795.
45. Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, Goldberg AC, Howard WJ, Jacobson MS, Kris-Etherton PM, Lennie TA, Levi M, Mazzone T, Pennathur S, American Heart Association Clinical Lipidology, Thrombosis, and Prevention Committee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Nursing; Council on the Kidney in Cardiovascular Disease Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2011 123 2292 2333. doi: 10.1161/CIR.0b013e3182160726.
46. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J., Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999 341 410 418. doi: 10.1056/NEJM199908053410604.
47. Keech A, Simes RJ, Barter P, FIELD study investigators Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005 366 1849 1861. doi: 10.1016/S0140-6736(05)67667-2.
48. Ginsberg HN, Elam MB, Lovato LC, ACCORD Study Group Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010 362 1563 1574. doi: 10.1056/NEJMoa1001282.
49. Bosch J, Gerstein HC, Dagenais GR, Díaz R, Dyal L, Jung H, Maggiono AP, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S, ORIGIN Trial Investigators n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med 2012 367 309 318. doi: 10.1056/NEJMoa1203859.
50. Utermann G., The mysteries of lipoprotein(a). Science 1989 246 904 910
51. Lp-PLA(2) Studies Collaboration Thompson A, Gao P, Orfei L, Watson S, Di A, ngelantonio E, Kaptoge S, Ballantyne C, Cannon CP, Criqui M, Cushman M, Hofman A, Packard C, Thompson SG, Collins R, Danesh J., Lp-PLA(2) Studies Collaboration Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010 375 1536 1544
52. STABILITY Investigators White HD, Held C, Stewart R, STABILITY Investigators Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med 2014 370 1702 1711
53. O'Donoghue ML, Braunwald E, White HD, SOLID-TIMI 52 Investigators Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. JAMA 2014 312 1006 1015. doi: 10.1001/jama.2014.11061.
54. Polfus LM, Gibbs RA, Boerwinkle E., Coronary heart disease and genetic variants with low phospholipase A2 activity. N Engl J Med 2015 372 295 296. doi: 10.1056/NEJMc1409673.
55. CARDIoGRAMplusC4D Consortium Deloukas P, Kanoni S, Willenborg C, CARDIoGRAMplusC4D Consortium Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet 2013 45 25 33